First-in-human study of KHN922 for advanced solid tumors
Part of Cancer clinical trials.
This is an early-stage trial testing a new drug called KHN922 in patients with advanced or hard-to-treat solid cancers. Researchers want to see if this drug is safe and if it can help slow or shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or unresectable solid cancer that hasn't responded well to standard treatments or you're not able to receive them
- Your tumor can be measured on CT or MRI scans
- You're in good enough health to handle treatment (ECOG performance status 0 or 1)
- You're between 18 and 75 years old with at least 3 months expected lifespan
- You haven't received other cancer treatments recently (timing depends on treatment type—typically 1-4 weeks)
- You don't have serious heart, lung, or uncontrolled blood pressure problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called MHB046C for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow their growth.
This trial tests an investigational medicine called HS-20117-2 for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if it is safe and if it might help shrink or control the tumor.
This trial tests a new drug called KH815 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and effective.
This Phase 1 trial tests KH617, a new treatment, in adults with advanced cancers to see if it can be given safely and whether it shows signs of benefit. It is especially focused on tumors that have few or no standard treatment options, including certain brain tumor recurrences.
This early-stage study tests an investigational drug (MHB088C) in adults with advanced or metastatic solid cancers that have gotten worse or can’t be treated with standard options. It aims to see if the drug is safe and can shrink tumors or control the cancer.
This trial tests a new drug called HSK39775 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective for people who have few other options.
Hear when a new Advanced Solid Tumors Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.